Prevalent cases of chronic hepatitis B in 7MM to reach 3.9 million in 2034

Japan is expected to record the highest number at 1.06 million cases.

The total number of prevalent cases of chronic hepatitis B (CHB) in the seven major markets (7MM) is projected to increase at an annual growth rate (AGR) of 0.04% from nearly 3.89 million in 2024 to 3.9 million in 2034, said GlobalData.

In contrast, the diagnosed prevalent cases of CHB are projected to decrease at an AGR of -0.13% to 2.06 million from 2.09 million during the period.

Whilst widespread vaccination and prevention efforts reduce the condition’s prevalence, expanded testing and case finding increase diagnoses.

“Despite being preventable by a widely available vaccine, CHB persists as a public health problem across the 7MM due to inadequate screening and treatment coverage,” said Molly Moran, Senior Epidemiologist at GlobalData.

Japan is expected to have the highest number of total prevalent cases in the 7MM, with approximately 1.06 million cases, whilst Spain is projected to have the fewest with about 286,000 cases.

“Continued focus on and investment in prevention of initial infection, especially in children, will result in fewer CHB cases requiring lifelong care,” Moran added.

7MM = US, France, Germany, Italy, Spain, UK, and Japan.